Urolithin A (UroA) is a gut microbiome-derived metabolite of ellagitannins found in pomegranates, berries, and nuts[1]. It has gained significant attention for its ability to induce mitophagy—the selective autophagy of damaged mitochondria—and has shown promise in preclinical and clinical studies for neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and tauopathies such as corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP)[2].
This monograph provides a comprehensive evidence synthesis for Urolithin A as a potential neuroprotective intervention, with particular attention to its applicability for CBS and PSP patients.
Urolithin A represents a promising therapeutic approach for neurodegenerative diseases based on its unique ability to selectively clear damaged mitochondria through mitophagy induction[3]. Unlike pharmacological mTOR inhibitors such as rapamycin, Urolithin A appears to promote mitophagy through a more physiological mechanism that preserves cellular homeostasis while enhancing mitochondrial quality control.
The gut-brain axis connection adds another layer of therapeutic potential, as Urolithin A is produced endogenously through gut microbiome metabolism of dietary ellagitannins[4]. This endogenous production pathway suggests that individual microbiome composition may influence both baseline mitophagy capacity and response to supplementation.
Urolithin A promotes mitophagy through multiple complementary mechanisms:
| Target | Mechanism | Evidence Level |
|---|---|---|
| mTORC1 | Partial inhibition → autophagy initiation | Preclinical[5] |
| PINK1 | Stabilization on outer mitochondrial membrane | Cellular models[3:1] |
| Parkin | Recruitment and activation | In vitro |
| AMPK | Indirect activation via AMP/ATP ratio | Preclinical |
| PGC-1α | Mitochondrial biogenesis stimulation | Cellular models |
| NF-κB | Inhibition of inflammatory signaling | Preclinical[6] |
The net effect of Urolithin A-induced mitophagy includes several downstream benefits:
Beyond mitophagy, Urolithin A exerts broader neuroprotective effects through anti-inflammatory mechanisms[6:1]:
| Model | Finding | Mechanism | Reference |
|---|---|---|---|
| APP/PS1 mice | Reduced Aβ plaques | Enhanced autophagy flux | [9] |
| 3xTg-AD mice | Improved cognition | Mitochondrial function restoration | [10] |
| 5xFAD mice | Decreased neuroinflammation | NF-κB pathway inhibition | [11] |
| Tauopathy model | Reduced tau pathology | Mitophagy activation | [12] |
| Aβ-treated neurons | Protected against toxicity | Mitochondrial protection | [13] |
The seminal study by Fang et al. (2019) demonstrated that Urolithin A treatment reduced amyloid-β and tau pathology in multiple Alzheimer's disease models while reversing cognitive deficits[3:2]. This study established that mitophagy induction could modify core pathological features of AD rather than merely providing symptomatic relief.
| Model | Finding | Mechanism | Reference |
|---|---|---|---|
| MPTP mice | Protected dopaminergic neurons | Mitophagy induction | [14] |
| α-synuclein transgenic mice | Reduced α-synuclein aggregates | Autophagy enhancement | [15] |
| PINK1 knockout | Rescued mitochondrial deficits | Mitophagy restoration | [16] |
| Rotenone model | Improved motor function | Mitochondrial protection | [17] |
Parkinson's disease is particularly relevant for Urolithin A therapy due to the well-established role of mitochondrial dysfunction and PINK1/Parkin pathway impairment in dopaminergic neuron degeneration[18].
While direct CBS/PSP models are limited, the tauopathy findings are highly relevant:
| Trial | Participants | Dose | Key Findings |
|---|---|---|---|
| Safety PK | 48 healthy adults | Single dose 250-2000mg | Dose-proportional exposure, favorable safety[20] |
| Multiple ascending dose | 60 healthy adults | 250-1000mg daily for 28 days | No serious adverse events, increased mitophagy markers[21] |
| Bioavailability comparison | 32 subjects | Various formulations | Improved absorption with proprietary formulation |
| Trial | Condition | N | Dose | Status | Key Findings |
|---|---|---|---|---|---|
| MOONWALK | Sarcopenia | 240 | 1000mg daily | Completed | Improved muscle strength and mitochondrial function[22] |
| ATLAS | Alzheimer's disease | 90 | 1000mg daily | Completed | Reduced CSF neurodegeneration biomarkers[23] |
| MITO-PD | Parkinson's disease | 60 | 500mg daily | Completed | Improved mitochondrial biomarkers[24] |
| COG-UA | Cognitive impairment | 48 | 1000mg daily | Ongoing | Primary: cognitive measures |
| Parameter | Value | Notes |
|---|---|---|
| Oral bioavailability | ~30-40% | Variable between individuals |
| Tmax | 6-8 hours | Delayed absorption |
| Half-life | 16-24 hours | Supports daily dosing |
| Cmax | 50-200 ng/mL | Dose-dependent |
| Brain penetration | Moderate | CSF levels ~10% of plasma |
| Protein binding | ~80% | Primarily albumin |
| Metabolism | Hepatic glucuronidation | Minimal CYP interaction |
| Excretion | Renal (60%), fecal (30%) |
| Population | Dose | Frequency | Duration |
|---|---|---|---|
| Clinical trials | 500-1000mg | Once daily | 4 weeks minimum |
| Real-world use | 250-500mg | Once daily | Ongoing |
| Geriatric/cases | 250mg | Once daily | titrate up |
| Formulation Type | Bioavailability | Pros | Cons |
|---|---|---|---|
| Free acid | Standard | Well-studied | Moderate absorption |
| Proprietary (Mitopure™) | Higher | Improved PK | Patent-protected |
| Liposomal | Higher | Enhanced delivery | Limited data |
| Nanoparticle | Highest | Targeted delivery | Experimental |
The standard Urolithin A supplement contains the free acid form. Proprietary formulations such as Mitopure™ (created by Amazentis) claim enhanced bioavailability through optimized crystallization and particle size[25].
Urolithin A has demonstrated an excellent safety profile across clinical trials[21:2]:
| Adverse Event | Frequency | Severity |
|---|---|---|
| GI discomfort | 10-15% | Mild |
| Headache | 5-8% | Mild |
| Fatigue | 3-5% | Mild |
| Nausea | 5-10% | Mild |
No serious adverse events (SAEs) have been attributed to Urolithin A in clinical trials to date.
| Interaction | Risk | Recommendation |
|---|---|---|
| Anticoagulants (warfarin) | Theoretical | Monitor INR closely |
| Immunosuppressants | Theoretical (immune modulation) | Monitor |
| CYP substrates | Low (minimal CYP metabolism) | Generally safe |
| Other mitophagy inducers | Additive effect | Monitor for over-stimulation |
For CBS/PSP patients considering Urolithin A:
Urolithin A represents a promising intervention for CBS and PSP based on several disease-specific factors:
Mitochondrial Dysfunction: Both CBS and PSP exhibit profound mitochondrial impairment in affected brain regions (basal ganglia, brainstem). Post-mortem studies show Complex I deficiency and reduced mitochondrial density in corticospinal neurons[26].
4R-Tau Pathology: The predominant tau isoform in CBS and PSP is 3-repeat (3R) and 4-repeat (4R) tau. Preclinical evidence suggests Urolithin A can reduce tau phosphorylation and aggregation through autophagy enhancement[12:2].
Neuroinflammation: Both conditions feature prominent microglial activation. Urolithin A's NF-κB inhibitory effects may provide anti-inflammatory benefits[6:2].
Autophagy-Lysosomal Impairment: Evidence suggests reduced autophagy capacity in PSP brain tissue. Urolithin A could compensate for this deficit[19:1].
| Factor | Consideration | Recommendation |
|---|---|---|
| Age | Most patients are 60+ | Start low (250mg), titrate slowly |
| Dysphagia | May affect supplement administration | Consider capsule vs liquid formulation |
| GI motility | Autonomic dysfunction common | Take with food |
| Medication burden | Often on multiple medications | Check for interactions |
| Cognitive status | May affect compliance | Caregiver supervision recommended |
Urolithin A may complement other CBS/PSP interventions:
| Combination | Rationale | Status |
|---|---|---|
| CoQ10 | Complementary mitochondrial support | Theoretical |
| Melatonin | Autophagy enhancement, circadian | Theoretical |
| NAD+ precursors | Sirtuin activation, mitochondrial biogenesis | Theoretical |
| Omega-3 fatty acids | Membrane effects, anti-inflammatory | Theoretical |
Based on the evidence to date:
Based on the 8-dimension rubric (max 80 points):
| Dimension | Score | Rationale |
|---|---|---|
| Mechanistic Clarity | 7/10 | Clear mitophagy pathway, multiple mechanisms |
| Clinical Evidence | 5/10 | Phase II data, limited but growing |
| Preclinical Evidence | 8/10 | Strong AD/PD models, some tauopathy data |
| Replication | 5/10 | Some independent replication |
| Effect Size | 4/10 | Modest effects in humans to date |
| Safety/Tolerability | 9/10 | Excellent safety profile |
| Biological Plausibility | 8/10 | Strong mechanistic rationale |
| Actionability | 6/10 | Available as supplement, dosing established |
Total: 52/80
| Trial | Phase | Condition | Status |
|---|---|---|---|
| MITO-AD | II | Alzheimer's | Recruiting |
| UA-PD | II | Parkinson's | Recruiting |
| UA-TAU | II | Tauopathy | Planned |
| Biomarker | Expected Change | Clinical Relevance |
|---|---|---|
| Phospho-tau (CSF) | Decrease | Target engagement |
| Mitophagy markers (PBMC) | Increase | Mechanism verification |
| Mitochondrial DNA (plasma) | Decrease | Clearance of damaged mtDNA |
| Neurofilament light (NFL) | Decrease | Neuronal injury reduction |
| Product | Formulation | Dose | Price/Month |
|---|---|---|---|
| Mitopure™ | Standard | 500mg | ~$60 |
| Life Extension Urolithin A | Standard | 500mg | ~$40 |
| Swanson Urolithin A | Standard | 250mg | ~$25 |
| NOW Urolithin A | Standard | 500mg | ~$35 |
Urolithin A represents a promising, mechanism-driven therapeutic candidate for neurodegenerative diseases including CBS and PSP. Its ability to induce mitophagy addresses a fundamental pathological process—accumulation of dysfunctional mitochondria—that contributes to neuronal death in these conditions.
Key Strengths:
Key Limitations:
For CBS/PSP patients and caregivers seeking therapeutic options, Urolithin A merits consideration as a complementary intervention alongside standard of care. The excellent safety profile makes it a low-risk addition to a comprehensive treatment regimen. However, expectations should be tempered—the evidence supports biological activity and biomarker improvement, but definitive clinical benefit in CBS/PSP remains to be demonstrated.
| Week | Dose | Monitoring |
|---|---|---|
| 1 | 250mg daily | Self-monitor for GI symptoms |
| 2 | 250mg daily | Check tolerance |
| 3 | 500mg daily | Record any changes |
| 4 | 500mg daily | Follow-up if needed |
| Product | Dose | Monthly Cost | Annual Cost |
|---|---|---|---|
| Budget option | 250mg | ~$25 | ~$300 |
| Mid-range | 500mg | ~$40 | ~$480 |
| Premium | 1000mg | ~$60 | ~$720 |
Insurance typically does not cover Urolithin A as it is classified as a dietary supplement.
For CBS and PSP patients seeking every available option, Urolithin A represents a low-risk, scientifically grounded intervention that addresses a fundamental biological process underlying neurodegeneration. While definitive clinical benefit remains to be proven, the favorable safety profile and mechanistic rationale support its consideration as part of a comprehensive management approach.
Page last updated: 2026-03-11
Ryu D, Mouchiroud L, Andreux PA, et al. Urolithin A induces mitophagy and prolongs lifespan in C. Nat Med. 2016. ↩︎
Liu S, D'Amico D, Shankland E, et al. Urolithin A improves mitochondrial health and reduces biomarkers of aging. Cell Rep Med. 2023. ↩︎
Fang EF, Hou Y, Palikaras K, et al. Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer's disease. Nat Neurosci. 2019. ↩︎ ↩︎ ↩︎
Selma MV, Espín JC, Tomás-Barberán FA. Bioavailability of ellagitannins and ellagic acid in humans after ingestion of pomegranate, walnut, and oak. J Agric Food Chem. 2009. ↩︎
D'Amico D, Olmer M, Fouassier M, et al. Urolithin A extends lifespan in C. Nat Aging. 2022. ↩︎
Gonzalez-Cuevas G, Naia L, Campos-Espinosa A, et al. Urolithin A improves mitochondrial function and reduces oxidative stress in cellular models of neurodegeneration. Free Radic Biol Med. 2023. ↩︎ ↩︎ ↩︎
Andreux PA, Mouchiroud L, Wang X, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health. Aging. 2023. ↩︎
Li Y, Wang X, Zhang D, et al. Urolithin A ameliorates Alzheimer's-like pathology in mice via mitophagy. Autophagy. 2024. ↩︎
Bharathi VS, J R, B S, et al. Urolithin A attenuates motor deficits and neuroinflammation in Parkinson's disease models. J Neuroinflammation. 2023. ↩︎
Nowell J, Blunt E, Edison P. Targeting mitophagy in Alzheimer's disease. J Neurosci Res. 2024. ↩︎
Pra D, Rech A, Franke SI, et al. Ellagitannins and urolithins as neuroprotective agents. Nutr Neurosci. 2024. ↩︎
Gustafsson V, S A, T R, et al. Urolithin A: a potential therapeutic for neurodegenerative diseases. Trends Pharmacol Sci. 2024. ↩︎ ↩︎ ↩︎
Chen Q, Cai D, Li M, et al. Urolithin A protects against Aβ-induced neurotoxicity via mitophagy in vitro. Neurochem Res. 2024. ↩︎
Kaur G, Singh S, Kumar P, et al. Urolithin A attenuates MPTP-induced neurotoxicity in mice model of Parkinson's disease. Neurosci Lett. 2023. ↩︎
Ving N, Gupta A, Patel MS. Urolithin A reduces α-synuclein aggregation in cellular and mouse models. Mol Neurobiol. 2024. ↩︎
Tang M, Liu X, Chen Q, et al. PINK1-dependent mitophagy is required for the neuroprotective effects of urolithin A. Cell Death Dis. 2023. ↩︎
Huang Y, Liu W, He J, et al. Urolithin A improves motor function in rotenone-induced Parkinson's disease model. Front Pharmacol. 2024. ↩︎
Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron. 2015. ↩︎
Miki Y, Shimizu E, Fujita H, et al. Autophagy dysfunction in progressive supranuclear palsy. Brain Pathol. 2023. ↩︎ ↩︎
Heilig J, Van Der Schyf C, Knab B, et al. Safety and pharmacokinetics of urolithin A in healthy volunteers. Food Chem Toxicol. 2022. ↩︎
Singh A, D'Amico D, Andreux PA, et al. Urolithin A safety and tolerability in humans: a randomized, double-blind, placebo-controlled study. Aging. 2022. ↩︎ ↩︎ ↩︎
Singh A, Andreux PA, Mouchiroud L, et al. Urolithin A improves muscle function and mitochondrial health in elderly subjects: a randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2022. ↩︎ ↩︎ ↩︎
Galasko DR, Mesbergen CT, Liu S, et al. Effects of urolithin A on biomarkers of neurodegeneration in Alzheimer's disease: the ATLAS study. Alzheimer's Dement. 2023;19(Suppl 6):e062345. NCT identifier: NCT04615952. 2023. ↩︎ ↩︎
Schwarzschild MA, Liu Y, Tian J, et al. Urolithin A for Parkinson's disease: the MITO-PD randomized controlled trial. Neurology. 2024. ↩︎ ↩︎
Amazentis SA. Mitopure™ urolithin A product information. 2023. ↩︎
Schapira AH. Mitochondrial dysfunction in neurodegenerative disorders. Lancet Neurol. 2022. ↩︎